Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 111 
Year : 2011  |  Volume : 17  |  Issue : 2  |  Page : 114-118

Effect of interferon treatment on hearing of patients with chronic Hepatitis C

1 Department of ENT, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 Department of Medicine, Division of Gastroenterology & Hepatology, Riyadh Military Hospital, Riyadh, Saudi Arabia
3 Gastroenterology Division, Department of Medicine, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Ahmed Al-Arfaj
Department of Otolaryngology, College of Medicine, King Saud University, P .O. Box 245, Riyadh 11411
Saudi Arabia
Login to access the Email id

Source of Support: College of Medicine Research Center (CMRC), King Saud University in Riyadh, Saudi Arabia (Grant No.06-553), Conflict of Interest: None

DOI: 10.4103/1319-3767.77240

Rights and Permissions

Background/Aim: Some reports in the literature have linked interferon therapy for the treatment of hepatitis C (HCV) with hearing loss. The aim of this study has been to examine the effects of interferon therapy on hearing of patients treated for HCV. Patients and Methods: Patients were recruited according to preset inclusion criteria from two centers. All patients received standard dose pegylated interferon (PEG-IFN a-2b or a-2a) plus ribavirin (RBV). All patients had pure-tone audiometry (PTA), tympanogram and distortion-product otoacoustic emission (DPOAE) before treatment, three months after initiation of treatment, and three months after completion of treatment. Results: Twenty one patients were prospectively recruited. The mean age was 45.7 years. The male to female ratio was 1.1:1. The mean PTA was 15.9 ± 5.3 before treatment, 17.4 ± 6.1 during treatment and 16.5 ± 5.1 after treatment. The differences between pre and mid, pre and post, as well as mid and post were not significantly different (P>0.05) in all audiological assessments. Conclusions: Our results indicate that PEG-IFN\RBV therapy does not have any impact on the hearing thresholds of patients with HCV.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded505    
    Comments [Add]    
    Cited by others 5    

Recommend this journal